Designs and develops biogas upgrading systems. Sells biogas upgrading systems to various industries. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
An average decline of 5% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 0.7× for every dollar of annual revenue.
No analyst target is on record for this company.
An investor who bought at the very peak is down 90% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $32.0M a year. A small number, but proof the product has real buyers.
There is $13.0M in the vault; even if every debt were paid off, $11.1M would remain.
It met or beat analyst expectations in 6 of the last 6 quarters — consistency is a promise kept.
A loss of $751K against $32.0M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.14. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 3 times as much as the market average. Big rallies — and big drops — can both happen fast.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.